Targeting Reactive Oxygen Species Metabolism to Induce Myeloma Cell Death

Mélody Caillot (1) , Hassan Dakik (2) , Frédéric Mazurier (2) , Brigitte Sola (3)

1 UNICAEN - Université de Caen Normandie
2 GICC EA 7501 - Groupe innovation et ciblage cellulaire (GICC), EA 7501 [2018-...]
3 GPMCND - Génomique et Médecine Personnalisée du Cancer et des Maladies Neuropsychiatriques

Multiple myeloma (MM) is a common hematological disease characterized by the accumulation of clonal malignant plasma cells in the bone marrow. Over the past two decades, new therapeutic strategies have significantly improved the treatment outcome and patients survival. Nevertheless, most MM patients relapse underlying the need of new therapeutic approaches. Plasma cells are prone to produce large amounts of immunoglobulins causing the production of intracellular ROS. Although adapted to high level of ROS, MM cells die when exposed to drugs increasing ROS production either directly or by inhibiting antioxidant enzymes. In this review, we discuss the efficacy of ROS-generating drugs for inducing MM cell death and counteracting acquired drug resistance specifically toward proteasome inhibitors.

Mots clés: multiple myeloma; ROS; antioxidant enzyme; proteasome inhibitor; NOX; mitochondria; redox balance; OXPHOS

Domaines: Cancer; Hématologie; Biologie cellulaire; Pharmacologie

Mélody Caillot, Hassan Dakik, Frédéric Mazurier, Brigitte Sola. Targeting Reactive Oxygen Species Metabolism to Induce Myeloma Cell Death. Cancers, 2021, 13 (10), pp.2411. ⟨10.3390/cancers13102411⟩. ⟨hal-03231403⟩